## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number: 3235-0287						
Estimated average burden						
hours per response.	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																
1. Name and Address of Reporting Person* Riedhammer Thomas M					2. Issuer Name and Ticker or Trading Symbol Ohr Pharmaceutical Inc [OHRP]							5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O OHR PHARMACEUTICAL INC., 800 THIRD AVENUE, 11TH FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 03/10/2015										itle below)		(specify below	ý)
(Street) NEW YORK, NY 10022				4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line)  X_Form filed by One Reporting Person  Form filed by More than One Reporting Person						
(Cir		(State)	(Zip)		Table I - Non-Derivative Securities Acquired, Disposed of, or B								f, or Benefi	cially Owned				
(Instr. 3)		2. Transaction Date (Month/Day/Ye	Exe ear) any	7	on Date, if	Co (In	(Instr. 8)		4. Securities Acqu (A) or Disposed o (Instr. 3, 4 and 5)		f (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)				o. Ownership Form:	Beneficial	
				(M	onth/	Day/Year	)	Code	V A	mount	(A) or (D)	S 7				Direct (D) or Indirect I) Instr. 4)	Ownership (Instr. 4)	
Common	Stock, \$0	.0001 par value										8	8,000			]	)	
			Table 1					Acquired	, Dispos	ed of,		cially O						
Derivative Conversion Date			3A. Deemed Execution Date, if	4. Transac Code	5. Number of Derivate Securities		er ntive s l (A) sed	Expiration Date (Month/Day/Year) A)			le securit	7. Title of Und Securit	e and Amor	unt	8. Price of Derivative Security (Instr. 5)			Ownershi (Instr. 4)
				Code	V	and 5)	(D)	Date Exercisa	able	Exp	iration	Title	Amo or Num of SI			Transaction(s) (Instr. 4)		
Option	\$ 4.74							04/30/	2013 <mark>(1</mark>	04/	30/2018	Comr	1116	,667		116,667	D	
Option	\$ 10.14	03/10/2015		A		84,000		03/10/	2015 <mark>(2</mark>	03/2	20/2020	Comr	1 54	000	\$ 0 (3)	84,000	D	
Repor	ting O	wners																

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Riedhammer Thomas M C/O OHR PHARMACEUTICAL INC. 800 THIRD AVENUE, 11TH FLOOR NEW YORK, NY 10022	X						

## **Signatures**

/s/ Thomas M. Riedhammer	03/11/2015
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 58,333 shares are currently unexercisable; half will vest on each of April 30, 2015, and April 30, 2016.
- (2) 63,000 options are currently unexercisable; 1/3rd will become exercisable on each of March 10, 2016, March 10, 2017 and March 10, 2018.

(3) Options granted pursuant to registrant's 2014 Stock Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.